Ocrelizumab for PPMS
Do you agree that the ocrelizumab trial results show that PPMS is modifiable?
Are the ocrelizumab trial results meaningful for pwPPMS?
Ocrelizumab will delay the need for using a wheelchair by about 4 years.
Do you think it is fair that only pwPPMS who can afford to pay privately should have access to ocrelizumab?
If ocrelizumab is not licensed by the EMA, or greenlighted by NICE, it will create a perverse situation were pwPPMS who can afford to pay for ocrelizumab privately will have access to the drug, whilst the majority of pwPPMS will not be treated.
What should be done to allow pwPPMS to access to ocrelizumab?
You can choose more than one option!
Ensure the EMA understands the unmet need and licenses ocrelizumab for PPMS
Ensure the payers and healthcare systems understand the unmet need and provide access to ocrelizumab for pwPPMS
Ask the MS Society and other stakeholders to make sure the EMA and Payers understand the unmet need on PPMS
Start a campaign to make the MS community aware how important this issue is for pwPPMS
Ask Roche to launch a compassionate access programme so pwPPMS can access ocrelizumab early
Ask Roche to explore ways to make ocrelizumab cost-effective for the treatment of PPMS
Arrange a PPMS protest to highlight the unmet need
What type of MS do you have?
What country do you live in?
No personal identifiers will be collected as part of this audit. By completing this survey you are consenting to the data you provide being analysed by Professor Giovannoni and the MS Team at Barts Health NHS Trust. Results of this audit will be analysed, written-up, presented to the Barts-MS team and may be submitted for publication.
Page 1 of 1
Never submit passwords through Google Forms.
This form was created inside of Gavin Giovannoni.
Terms of Service